BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.

Autor: Pagnano KB; a 1 Hemocentro-UNICAMP , University of Campinas, Campinas , São Paulo, Brazil., Bendit I; b 2 Laboratório de Biologia Tumoral , University of São Paulo, São Paulo , São Paulo, Brazil., Boquimpani C; c 3 Hemorio, Rio de Janeiro , Rio de Janeiro, Brazil., De Souza CA; a 1 Hemocentro-UNICAMP , University of Campinas, Campinas , São Paulo, Brazil., Miranda EC; a 1 Hemocentro-UNICAMP , University of Campinas, Campinas , São Paulo, Brazil., Zalcberg I; d 4 Instituto Nacional do Câncer, Rio de Janeiro , Rio de Janeiro, Brazil., Larripa I; e 5 Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires , Buenos Aires, Argentina., Nardinelli L; b 2 Laboratório de Biologia Tumoral , University of São Paulo, São Paulo , São Paulo, Brazil., Silveira RA; a 1 Hemocentro-UNICAMP , University of Campinas, Campinas , São Paulo, Brazil., Fogliatto L; f 6 Hospital das Clínicas de Porto Alegre, Porto Alegre , Rio Grande do Sul, Brazil., Spector N; g 7 Federal University of Rio de Janeiro , Rio de Janeiro , Rio de Janeiro, Brazil., Funke V; h 8 Universidade Federal do Paraná , Curitiba, Paraná, Brazil., Pasquini R; h 8 Universidade Federal do Paraná , Curitiba, Paraná, Brazil., Hungria V; i 9 Santa Casa de São Paulo, São Paulo , São Paulo, Brazil., Chiattone CS; i 9 Santa Casa de São Paulo, São Paulo , São Paulo, Brazil., Clementino N; j 10 Universidade Federal de Minas Gerais , Belo Horizonte , Minas Gerais, Brazil., Conchon M; k 11 Hospital Santa Marcelina , São Paulo, São Paulo, Brazil., Moiraghi EB; l 12 Hospital Ramos Mejía , Buenos Aires, Argentina., Lopez JL; m 13 Banco Municipal de Sangre del DC , Caracas, Venezuela., Pavlovsky C; n 14 FUNDALEU , Buenos Aires, Argentina., Pavlovsky MA; n 14 FUNDALEU , Buenos Aires, Argentina., Cervera EE; o 15 INCAN , Mexico, D.F., Mexico., Meillon LA; p 16 Centro Médico Nacional Siglo XXI , Mexico, D.F., Mexico., Simões B; q 17 University of São Paulo , Ribeirão Preto, São Paulo, Brazil., Hamerschlak N; r 18 Hospital Israelita Albert Einstein , São Paulo, São Paulo, Brazil., Bozzano AH; s 19 Hospital Maciel , Montevideo, Uruguay., Mayta E; t 20 Instituto Oncologico Nacional , Panamá, Panama., Cortes J; u 21 MD Anderson Cancer Center , Houston, Texas, USA., Bengió RM; e 5 Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires , Buenos Aires, Argentina.
Jazyk: angličtina
Zdroj: Cancer investigation [Cancer Invest] 2015; Vol. 33 (9), pp. 451-8. Date of Electronic Publication: 2015 Aug 17.
DOI: 10.3109/07357907.2015.1065499
Abstrakt: This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje